Overview


According to FutureWise analysis the market for colorectal cancer drugs in 2023 is US$ 14.13 billion, and is expected to reach US$ 19.22 billion by 2031 at a CAGR of 3.90%.

Market for colorectal cancer drugs consists of the sale of colorectal cancer drugs. A cancer affecting the large intestine and the rectum is called colon cancer or bowel cancer. It is also known as a colon tumor or rectal cancer, depending on where it begins. For high-risk resectable colorectal cancer, there are few adjuvant/neoadjuvant medicines available. Due to the lack of pipeline agents in this setting, it presents a good opportunity for the development of effective treatments that can improve cure rates for patients who have undergone resection. For resectable CRC, the majority of treatments consist of more affordable chemotherapeutic regimens and generic medications. There are several lifestyle factors connected with colorectal cancer, including age, family history, being overweight or obese, not exercising regularly, smoking, and heavy alcohol use. Patients with non-metastatic colorectal cancer usually receive surgical resection followed by radiotherapy or chemotherapy, whereas patients with metastatic colorectal cancer generally receive systemic chemotherapy. Hospitals generally offer surgical therapy, radiation therapy, chemotherapy and targeted therapy. Colorectal cancer is likely to grow in popularity due to the rising health awareness among masses and the increasing prevalence of colorectal cancer among individuals.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Colorectal Cancer Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Colorectal Cancer Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • MerckCo. Inc
  • Roche
  • Sanofi
  • Amgen
  • Pfizer Inc.
  • Abbott Laboratories
  • Taiho Pharma
  • Novartis
  • GlaxoSmithKline
  • Onyx
  • TAKEDA PHARMACEUTICALS
  • Bristol-Myers Squib
  • Sumitomo Dainippon Pharma
  • Array BioPharma
  • Eli Lilly
  • RANDOX LABORATORIES
  • Suzhou Zelgen Biopharmaceuticals
  • Beckman Coulter Inc
  • Regeneron
  • EDP Biotech
  • Genomic Tree
  • Metabiomics Corporation
  • SIEMENS HEALTHCARE
  • Suzhou Zelgen Biopharmaceuticals
  • Sumitomo Dainippon Pharma
  • EPIGENOMICS

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Type

  • Vascular Endothelial Growth Factor (VEGF) Inhibitors
  • Epidermal Growth Factor Receptor (EGFR) Inhibitors
  • Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
  • BRAF or MEK Inhibitors
  • Tyrosine Kinase (TKI) Inhibitors
  • Immunomodulators

By Distribution Channels

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Others

By Class

  • Immunotherapy
  • Chemotherapy
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Colorectal Cancer Drugs Market By Type, By Distribution Channels, By Class and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Colorectal Cancer Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Colorectal Cancer Drugs Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Colorectal Cancer Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Colorectal Cancer Drugs Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Vascular Endothelial Growth Factor (VEGF) Inhibitors
        2. Epidermal Growth Factor Receptor (EGFR) Inhibitors
        3. Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
        4. BRAF or MEK Inhibitors
        5. Tyrosine Kinase (TKI) Inhibitors
        6. Immunomodulators

  • 8.   Colorectal Cancer Drugs Market, By Distribution Channels Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals Pharmacies
        2. Retail Pharmacies
        3. Others

  • 9.   Colorectal Cancer Drugs Market, By Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Immunotherapy
        2. Chemotherapy
        3. Others

  • 10.   North America Colorectal Cancer Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Colorectal Cancer Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Colorectal Cancer Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Colorectal Cancer Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •           1. MerckCo. Inc
                 1.1. Company Overview
                 1.2. Product Portfolio
                 1.3. SWOT Analysis
                 1.4. Financial Overview
                 1.5. Strategic Overview
                2. Roche
                 2.1. Company Overview
                 2.2. Product Portfolio
                 2.3. SWOT Analysis
                 2.4. Financial Overview
                 2.5. Strategic Overview
                3. Sanofi
                 3.1. Company Overview
                 3.2. Product Portfolio
                 3.3. SWOT Analysis
                 3.4. Financial Overview
                 3.5. Strategic Overview
                4. Amgen
                 4.1. Company Overview
                 4.2. Product Portfolio
                 4.3. SWOT Analysis
                 4.4. Financial Overview
                 4.5. Strategic Overview
                5. Pfizer Inc.
                 5.1. Company Overview
                 5.2. Product Portfolio
                 5.3. SWOT Analysis
                 5.4. Financial Overview
                 5.5. Strategic Overview
                6. Abbott Laboratories
                 6.1. Company Overview
                 6.2. Product Portfolio
                 6.3. SWOT Analysis
                 6.4. Financial Overview
                 6.5. Strategic Overview
                7. Taiho Pharma
                 7.1. Company Overview
                 7.2. Product Portfolio
                 7.3. SWOT Analysis
                 7.4. Financial Overview
                 7.5. Strategic Overview
                8. Novartis
                 8.1. Company Overview
                 8.2. Product Portfolio
                 8.3. SWOT Analysis
                 8.4. Financial Overview
                 8.5. Strategic Overview
                9. GlaxoSmithKline
                 9.1. Company Overview
                 9.2. Product Portfolio
                 9.3. SWOT Analysis
                 9.4. Financial Overview
                 9.5. Strategic Overview
                10. Onyx
                 10.1. Company Overview
                 10.2. Product Portfolio
                 10.3. SWOT Analysis
                 10.4. Financial Overview
                 10.5. Strategic Overview
                11. TAKEDA PHARMACEUTICALS
                 11.1. Company Overview
                 11.2. Product Portfolio
                 11.3. SWOT Analysis
                 11.4. Financial Overview
                 11.5. Strategic Overview
                12. Bristol-Myers Squib
                 12.1. Company Overview
                 12.2. Product Portfolio
                 12.3. SWOT Analysis
                 12.4. Financial Overview
                 12.5. Strategic Overview
                13. Sumitomo Dainippon Pharma
                 13.1. Company Overview
                 13.2. Product Portfolio
                 13.3. SWOT Analysis
                 13.4. Financial Overview
                 13.5. Strategic Overview
                14. Array BioPharma
                 14.1. Company Overview
                 14.2. Product Portfolio
                 14.3. SWOT Analysis
                 14.4. Financial Overview
                 14.5. Strategic Overview
                15. Eli Lilly
                 15.1. Company Overview
                 15.2. Product Portfolio
                 15.3. SWOT Analysis
                 15.4. Financial Overview
                 15.5. Strategic Overview
                16. RANDOX LABORATORIES
                 16.1. Company Overview
                 16.2. Product Portfolio
                 16.3. SWOT Analysis
                 16.4. Financial Overview
                 16.5. Strategic Overview
                17. Suzhou Zelgen Biopharmaceuticals
                 17.1. Company Overview
                 17.2. Product Portfolio
                 17.3. SWOT Analysis
                 17.4. Financial Overview
                 17.5. Strategic Overview
                18. Beckman Coulter Inc
                 18.1. Company Overview
                 18.2. Product Portfolio
                 18.3. SWOT Analysis
                 18.4. Financial Overview
                 18.5. Strategic Overview
                19. Regeneron
                 19.1. Company Overview
                 19.2. Product Portfolio
                 19.3. SWOT Analysis
                 19.4. Financial Overview
                 19.5. Strategic Overview
                20. EDP Biotech
                 20.1. Company Overview
                 20.2. Product Portfolio
                 20.3. SWOT Analysis
                 20.4. Financial Overview
                 20.5. Strategic Overview
                21. Genomic Tree
                 21.1. Company Overview
                 21.2. Product Portfolio
                 21.3. SWOT Analysis
                 21.4. Financial Overview
                 21.5. Strategic Overview
                22. Metabiomics Corporation
                 22.1. Company Overview
                 22.2. Product Portfolio
                 22.3. SWOT Analysis
                 22.4. Financial Overview
                 22.5. Strategic Overview
                23. SIEMENS HEALTHCARE
                 23.1. Company Overview
                 23.2. Product Portfolio
                 23.3. SWOT Analysis
                   23.4. Financial Overview
                   23.5. Strategic Overview
                24. Suzhou Zelgen Biopharmaceuticals
                 24.1. Company Overview
                 24.2. Product Portfolio
                 24.3. SWOT Analysis
                 24.4. Financial Overview
                 24.5. Strategic Overview
                25. Sumitomo Dainippon Pharma
                 25.1. Company Overview
                 25.2. Product Portfolio
                 25.3. SWOT Analysis
                 25.4. Financial Overview
                 25.5. Strategic Overview
                26. EPIGENOMICS
                 26.1. Company Overview
                 26.2. Product Portfolio
                 26.3. SWOT Analysis
                 26.4. Financial Overview
                 26.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients